| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
Revenue  | 1,529 | 1,430 | 1,439 | 1,327 | 1,466 | 1,405 | 1,365 | 1,444 | 1,576 | 1,545 | 1,628 | 2,045 | 2,247 | 2,056 | 2,249 | 2,382 | 2,346 | 2,163 | 2,249 | 1,544 | 1,563 | 1,175 | 1,631 | 1,838 | 1,614 | 1,617 | 1,638 | 1,304 | 1,513 | 1,452 | 1,598 | 1,543 | 1,682 | 1,575 | 1,686 | 1,714 | 1,764 | 2,130 | 1,764 | 1,823 |
| Expenses | 1,323 | 1,121 | 1,129 | 1,061 | 1,192 | 1,051 | 1,045 | 1,126 | 1,293 | 1,219 | 1,336 | 1,651 | 1,794 | 1,663 | 1,828 | 1,899 | 2,262 | 1,747 | 1,798 | 1,141 | 1,131 | 977 | 1,242 | 1,293 | 1,216 | 1,269 | 1,319 | 1,116 | 1,280 | 1,259 | 1,440 | 1,408 | 1,459 | 1,419 | 1,439 | 1,459 | 1,656 | 1,480 | 1,477 | 1,554 |
| EBITDA | 206 | 309 | 310 | 266 | 274 | 354 | 319 | 318 | 283 | 327 | 293 | 394 | 453 | 393 | 422 | 483 | 83 | 415 | 451 | 403 | 432 | 199 | 389 | 546 | 398 | 348 | 319 | 187 | 233 | 192 | 158 | 134 | 223 | 156 | 247 | 255 | 108 | 650 | 287 | 269 |
| Operating Profit % | 13 % | 21 % | 21 % | 20 % | 19 % | 25 % | 23 % | 22 % | 17 % | 21 % | 18 % | 19 % | 19 % | 19 % | 19 % | 19 % | 4 % | 19 % | 20 % | 24 % | 24 % | 13 % | 20 % | 26 % | 22 % | 21 % | 19 % | 14 % | 15 % | 13 % | 9 % | 8 % | 12 % | 9 % | 14 % | 12 % | 5 % | 14 % | 15 % | 14 % |
| Depreciation | 66 | 70 | 75 | 75 | 127 | 72 | 72 | 73 | 75 | 73 | 79 | 82 | 182 | 88 | 90 | 98 | 95 | 103 | 117 | 84 | 98 | 82 | 85 | 96 | 86 | 88 | 100 | 93 | 101 | 95 | 94 | 94 | 271 | 90 | 97 | 95 | 101 | 91 | 91 | 91 |
| Interest | 85 | 91 | 92 | 89 | 99 | 83 | 80 | 98 | 80 | 69 | 66 | 77 | 73 | 51 | 54 | 53 | 62 | 73 | 72 | 49 | 47 | 48 | 47 | 46 | 43 | 35 | 35 | 37 | 40 | 40 | 42 | 51 | 56 | 62 | 66 | 71 | 73 | 71 | 61 | 56 |
| Profit Before Tax | 68 | 168 | 161 | 145 | 69 | 218 | 193 | 166 | 160 | 203 | 168 | 261 | 227 | 286 | 302 | 356 | -40 | 269 | 292 | 294 | 358 | 106 | 299 | 431 | 297 | 247 | 208 | 70 | 106 | 69 | 36 | 9 | -86 | 25 | 98 | 101 | -54 | 500 | 144 | 131 |
| Tax | 25 | 37 | 36 | 24 | 58 | 54 | 50 | 48 | 11 | 60 | 43 | 48 | 74 | 86 | 92 | 88 | 61 | 84 | 43 | 90 | 98 | 18 | 75 | 121 | 83 | 86 | 65 | 19 | 47 | 22 | 32 | 25 | 14 | 19 | 36 | 35 | 8 | 18 | 42 | 30 |
| Net Profit | 43 | 130 | 125 | 122 | 11 | 164 | 144 | 118 | 149 | 144 | 126 | 213 | 152 | 200 | 210 | 268 | -101 | 185 | 249 | 203 | 261 | 88 | 224 | 310 | 214 | 161 | 143 | 51 | 59 | 47 | 5 | -16 | -101 | 6 | 62 | 66 | -62 | 482 | 103 | 101 |
| EPS in ₹ | 2.68 | 8.28 | 8.11 | 7.90 | 0.72 | 10.39 | 9.29 | 7.66 | 9.63 | 9.44 | 8.23 | 13.64 | 9.94 | 13.00 | 13.50 | 16.74 | -6.38 | 11.61 | 15.66 | 12.77 | 16.35 | 5.53 | 14.06 | 19.46 | 13.43 | 10.09 | 8.97 | 3.20 | 3.74 | 2.96 | 0.34 | -0.98 | -6.15 | 0.40 | 3.94 | 4.22 | -3.69 | 30.44 | 6.47 | 6.37 |
Jubilant Pharmova
910.00
-42.65
(-4.48%)
Market Cap
14,494.58 Cr
EPS
4.87
PE Ratio
45.04
Dividend Yield
0.52 %
Industry
Healthcare52 Week High
1,309.90
52 Week Low
617.05
PB Ratio
2.56
Debt to Equity
0.68
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from3 analysts
Peer Comparison Compare Peers on Screener
| Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,787.40 | #1 4,28,857.13 | 36.71 | #1 49,887.20 | 12.06 | #1 9,648 | 13.77 | 59.27 | |
6,012.50 | 1,59,612.98 | 79.83 | 8,184.00 | 0.89 | 1,600 | #1 64.53 | 57.99 | |
1,525.90 | 1,23,233.96 | 25.11 | 26,520.70 | 14.17 | 4,155 | 47.38 | 57.43 | |
3,238.90 | 1,09,619.09 | 60.42 | 10,785.70 | 11.59 | 1,656 | 13.54 | 52.37 | |
2,557.50 | 1,05,516.96 | 52.60 | 10,615.60 | 19.57 | 1,942 | -16.38 | 59.98 | |
1,174.80 | 98,031.82 | #1 18.66 | 28,905.40 | 12.36 | 5,578 | 1.69 | 54.12 | |
2,019.60 | 92,203.01 | 33.50 | 20,141.50 | #1 19.94 | 1,936 | 38.82 | 50.28 | |
859.65 | 86,500.90 | 19.53 | 19,831.50 | 13.82 | 3,831 | 29.92 | 46.44 | |
1,220.10 | 70,863.61 | 20.72 | 29,559.20 | 17.55 | 3,169 | -10.04 | 58.85 | |
29,705.00 | 63,121.05 | 47.82 | 6,097.20 | 10.80 | 1,201 | 16.01 | 45.94 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
7.15 %
Net Income Growth
-212.02 %
Cash Flow Change
47.01 %
ROE
-211.67 %
ROCE
99.13 %
EBITDA Margin (Avg.)
11.09 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 8,619 | 8,824 | 9,041 | 9,618 | 11,469 | 12,522 | 8,918 | 9,991 | 11,157 | 11,549 |
| Fixed Assets | 4,911 | 5,104 | 5,107 | 5,401 | 5,648 | 6,340 | 4,609 | 4,871 | 5,183 | 5,091 |
| Current Assets | 2,715 | 2,875 | 2,948 | 3,190 | 4,585 | 5,038 | 2,953 | 3,509 | 3,762 | 3,876 |
| Capital Work in Progress | 597 | 611 | 684 | 671 | 901 | 768 | 897 | 1,090 | 1,562 | 2,103 |
| Investments | 0 | 85 | 103 | 124 | 115 | 69 | 241 | 239 | 256 | 42 |
| Other Assets | 3,111 | 3,023 | 3,147 | 3,423 | 4,804 | 5,344 | 3,171 | 3,792 | 4,156 | 4,312 |
| Total Liabilities | 8,619 | 8,824 | 9,041 | 9,618 | 11,469 | 12,522 | 8,918 | 9,991 | 11,157 | 11,549 |
| Current Liabilities | 2,129 | 2,464 | 1,684 | 2,005 | 2,090 | 2,619 | 1,049 | 1,592 | 1,772 | 1,889 |
| Non Current Liabilities | 4,036 | 3,432 | 3,968 | 3,578 | 4,570 | 4,299 | 3,128 | 3,083 | 3,993 | 4,238 |
| Total Equity | 2,454 | 2,928 | 3,389 | 4,035 | 4,809 | 5,604 | 4,742 | 5,316 | 5,392 | 5,421 |
| Reserve & Surplus | 2,438 | 2,951 | 3,421 | 4,071 | 4,793 | 5,588 | 4,726 | 5,303 | 5,383 | 5,418 |
| Share Capital | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | -82 | -52 | 117 | -212 | 761 | 225 | -652 | 482 | 30 | -58 |
| Investing Activities | -362 | -309 | -465 | -614 | -1,018 | -267 | -727 | -323 | -474 | -596 |
| Operating Activities | 783 | 1,099 | 1,269 | 1,303 | 1,122 | 1,543 | 1,784 | 838 | 661 | 971 |
| Financing Activities | -503 | -843 | -686 | -901 | 657 | -1,050 | -1,709 | -33 | -157 | -433 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
| Promoter | 50.68 % | 50.68 % | 50.68 % | 50.68 % | 50.68 % | 50.68 % | 50.68 % | 50.68 % | 50.68 % | 50.68 % | 50.68 % | 50.68 % | 50.68 % | 50.68 % | 50.68 % | 50.68 % | 50.68 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 23.21 % | 0.00 % | 19.06 % | 19.49 % | 17.94 % | 16.96 % | 17.22 % |
| DIIs | 0.78 % | 1.15 % | 0.40 % | 0.43 % | 0.05 % | 0.04 % | 0.39 % | 1.62 % | 0.40 % | 1.63 % | 1.65 % | 1.50 % | 3.78 % | 4.07 % | 5.66 % | 6.98 % | 7.05 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 1.24 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 16.07 % | 16.98 % | 19.03 % | 18.97 % | 19.27 % | 19.35 % | 19.01 % | 18.68 % | 18.69 % | 18.25 % | 18.24 % | 18.76 % | 18.71 % | 17.79 % | 18.09 % | 18.09 % | 17.75 % |
| Others | 32.47 % | 31.19 % | 29.89 % | 29.92 % | 30.00 % | 29.93 % | 29.92 % | 29.02 % | 28.98 % | 29.44 % | 6.22 % | 29.06 % | 7.77 % | 7.97 % | 7.63 % | 7.30 % | 7.31 % |
| No of Share Holders | 0 | 61,942 | 87,493 | 1,13,776 | 1,09,420 | 1,08,063 | 1,09,410 | 1,05,632 | 97,935 | 93,375 | 89,376 | 86,588 | 92,264 | 81,992 | 89,456 | 1,02,442 | 96,526 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 3 | 3 | 4.5 | 5 | 5 | 5 | 5 | 5 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.36 | 0.45 | 1.81 | 0.73 | 1.29 | 1.79 | 0.88 | 0.56 | 0.00 |
Corporate Action
Login to View
This information is available only for users of ScanX and Dhan.To proceed ahead,
LoginOpen Account
Announcements
Update On Material Development About The Disclosure Made On February 25 2025
6 days ago
6 days agoCompliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 10, 2025
Apr 10, 2025Amended And Restated Deed Of Private Trust Dated March 25 2025Mar 25, 2025
Mar 25, 2025Closure of Trading WindowMar 24, 2025
Mar 24, 2025Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Jubilant Biosys Innovative Research Services Pte Limited Singapore Has Executed Shareholders Agreement And Other Transition Agreements With PieMar 20, 2025
Mar 20, 2025Announcement Under Regulation 30 - USFDA Report For Jubilant Cadista Pharmaceuticals Inc. USAMar 12, 2025
Mar 12, 2025Rumour verification - Regulation 30(11)Feb 25, 2025
Feb 25, 2025Rumour verification - Regulation 30(11)Feb 25, 2025
Feb 25, 2025Audio Recording Of Investors / Analysts MeetingFeb 24, 2025
Feb 24, 2025Presentation For Investor And Analyst MeetFeb 24, 2025
Feb 24, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 05, 2025
Feb 05, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 01, 2025
Feb 01, 2025Integrated Filing (Financial)Jan 31, 2025
Jan 31, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 31, 2025
Jan 31, 2025Unaudited Results For The Quarter Ended December 31 2024Jan 31, 2025
Jan 31, 2025Board Meeting Outcome for Outcome Of Board MeetingJan 31, 2025
Jan 31, 2025Announcement Under Regulation 30 - Jubilant Biosys Innovative Research Services Pte Limited Singapore (JBIRSPL) A Subsidiary Of Jubilant Biosys Limited A Wholly Owned Subsidiary Of The Company Has ExeJan 29, 2025
Jan 29, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 27, 2025
Jan 27, 2025The Company Has Informed The Prepayment Of USD 25 Million Term Loan Equivalent To Rs. 214 Cr.Jan 24, 2025
Jan 24, 2025Board Meeting Intimation for Intimation For Board Meeting Scheduled On January 31 2025 To Consider The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Nine Jan 23, 2025
Jan 23, 2025USFDA Inspection In Companys Subsidiary Jubilant Cadista Pharmaceuticals Inc.Jan 17, 2025
Jan 17, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 15, 2025
Jan 15, 2025Announcement under Regulation 30 (LODR)-Credit RatingDec 10, 2024
Dec 10, 2024Deferment Of Investor/ Analysts MeetingNov 05, 2024
Nov 05, 2024Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 27, 2024
Oct 27, 2024Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 25, 2024
Oct 25, 2024Approval Of Unaudited Financial Results For Quarter And Half Year Ended September 30, 2024Oct 25, 2024
Oct 25, 2024Board Meeting Outcome for Outcome Of The Board Meeting Held On October 25, 2024 - Approval Of Unaudited Financial Results For Quarter And Half Year Ended September 30, 2024Oct 25, 2024
Oct 25, 2024Announcement - Voluntary Prepayment Of USD 25 Million Term Loan, Equivalent To Rs. 210 CrOct 24, 2024
Oct 24, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 19, 2024
Oct 19, 2024Board Meeting Intimation for Intimation Of Board MeetingOct 17, 2024
Oct 17, 2024Deletion Of Tax Deman Raised On Jubilant Generics Ltd - Step Down SusbsidiaryOct 10, 2024
Oct 10, 2024Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 09, 2024
Oct 09, 2024Announcement under Regulation 30 (LODR)-Updates on AcquisitionOct 04, 2024
Oct 04, 2024Announcement under Regulation 30 (LODR)-Change in ManagementOct 01, 2024
Oct 01, 2024Announcement Under Regulation 30Oct 01, 2024
Oct 01, 2024Closure of Trading WindowSep 30, 2024
Sep 30, 2024Communication From USFDASep 28, 2024
Sep 28, 2024Communication From USFDA.Sep 26, 2024
Sep 26, 2024Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011Sep 20, 2024
Sep 20, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 11, 2024
Sep 11, 2024Announcement Under Regulation 30 - Communication From USFDASep 10, 2024
Sep 10, 2024Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportAug 30, 2024
Aug 30, 2024Shareholder Meeting / Postal Ballot-Outcome of AGMAug 30, 2024
Aug 30, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateAug 24, 2024
Aug 24, 2024Postal Ballot Results Alongwith Scrutinizers ReportAug 23, 2024
Aug 23, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 16, 2024
Aug 16, 2024Jubilant Biosys Limited, A Wholly Owned Subsidiary Of The Company, Has Signed And Issued A 'Put Option Offer' To Pierre Fabre Laboratories, Which Sets Forth An Offer To Acquire 80% Equity Capital (Approx. Euro 4.4 Million Over A Period Of 2 Years) In A New Company To Be Incorporated In France, Which New Company Shall Acquire Pierre Fabre'S R&D Centre (Including R&D Site And R&D Activities) At Saint Julien, France.Aug 16, 2024
Aug 16, 2024Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 09, 2024
Aug 09, 2024Reg. 34 (1) Annual Report.Aug 09, 2024
Aug 09, 2024Technical Indicators
RSI(14)
Neutral 49.48
ATR(14)
Volatile 44.73
STOCH(9,6)
Neutral 73.26
STOCH RSI(14)
Neutral 66.23
MACD(12,26)
Bullish 4.44
ADX(14)
Weak Trend 10.38
UO(9)
Bearish 50.45
ROC(12)
Downtrend And Accelerating -2.07
WillR(14)
Neutral -44.04
About Jubilant Pharmova
Jubilant Pharmova Limited is an integrated global pharmaceutical and life sciences company. It operates in segments including Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing Organisation-Sterile Injectables, Generics, Contract Research, Development and Manufacturing Organisation, and Proprietary Novel Drugs. The company manufactures and supplies Active Pharmaceutical Ingredients, Solid Dosage Formulations, Radiopharmaceuticals, and Allergy Therapy Products. It has 6 US FDA approved manufacturing facilities in India, USA and Canada, and a network of over 48 radiopharmacies in the USA. Jubilant Pharmova provides drug discovery and development services, and is working on addressing unmet medical needs in oncology and autoimmune diseases. The company has filed numerous Drug Master Files in various countries and has expanded its manufacturing and research capabilities in recent years.
Website
Chairperson NameShyam S Bhartia
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
